Kim R - Search Results

1

General overview of neo-adjuvant therapy for hepatocellular carcinoma before liver transplantation: necessity or option?

Fujiki M, Aucejo F, Kim R. Fujiki M, et al. Among authors: kim r. Liver Int. 2011 Sep;31(8):1081-9. doi: 10.1111/j.1478-3231.2011.02473.x. Liver Int. 2011. PMID: 22008644 Review.

2

Neoadjuvant therapy for hepatocellular carcinoma: is there an optimal approach?

Almhanna K, Kalmadi S, Pelley R, Kim R. Almhanna K, et al. Among authors: kim r. Oncology (Williston Park). 2007 Aug;21(9):1116-22; discussion 1122, 1124, 1127-8. Oncology (Williston Park). 2007. PMID: 17910314 Free article. Review.

3

Vascular endothelial growth factor receptor 2 expression in non-tumorous cirrhotic liver is higher when hepatoma is beyond Milan criteria.

Aucejo F, Kim R, Zein N, Quintini C, Uso TD, Lopez R, Eghtesad B, Fung J, Miller C, Yerian L. Aucejo F, et al. Among authors: kim r. Liver Transpl. 2009 Feb;15(2):169-76. doi: 10.1002/lt.21678. Liver Transpl. 2009. PMID: 19177438 Free article.

4

Adjuvant treatment after orthotopic liver transplantation: is it really necessary?

Kim R, Tan A, Estfan B, Aucejo F. Kim R, et al. Oncology (Williston Park). 2009 Dec;23(14):1276-81. Oncology (Williston Park). 2009. PMID: 20120841 Free article.

5

Is there a role for adjuvant treatment after hepatic resection for hepatocellular carcinoma?

Tan A, Aucejo F, Kim R. Tan A, et al. Among authors: kim r. Oncology. 2010;78(3-4):161-71. doi: 10.1159/000315577. Epub 2010 Jun 8. Oncology. 2010. PMID: 20530972 Review.

6

Safe use of sorafenib in a patient undergoing salvage liver transplantation for recurrent hepatocellular carcinoma after hepatic resection.

Kim R, Menon N, Aucejo F. Kim R, et al. Med Oncol. 2011 Dec;28(4):1044-7. doi: 10.1007/s12032-010-9625-x. Epub 2010 Jul 16. Med Oncol. 2011. PMID: 20635167

7

Radiologic complete response with sirolimus and sorafenib in a hepatocellular carcinoma patient who relapsed after orthotopic liver transplantation.

Kim R, Aucejo F. Kim R, et al. J Gastrointest Cancer. 2011 Mar;42(1):50-3. doi: 10.1007/s12029-010-9196-2. J Gastrointest Cancer. 2011. PMID: 20714941

8

Safety and feasibility of using sorafenib in recurrent hepatocellular carcinoma after orthotopic liver transplantation.

Kim R, El-Gazzaz G, Tan A, Elson P, Byrne M, Chang YD, Aucejo F. Kim R, et al. Oncology. 2010;79(1-2):62-6. doi: 10.1159/000319548. Epub 2010 Nov 11. Oncology. 2010. PMID: 21071991

9

Insulin-like growth factor I receptor β expression in hepatocellular carcinoma.

Liu X, Jiang W, Aucejo F, Kim R, Miller C, Byrne M, Lopez R, Yerian L. Liu X, et al. Among authors: kim r. Hum Pathol. 2011 Jun;42(6):882-91. doi: 10.1016/j.humpath.2010.10.007. Epub 2011 Feb 2. Hum Pathol. 2011. PMID: 21292299

10

What is the indication for sorafenib in hepatocellular carcinoma? A clinical challenge.

Kim R, Byrne MT, Tan A, Aucejo F. Kim R, et al. Oncology (Williston Park). 2011 Mar;25(3):283-91, 295. Oncology (Williston Park). 2011. PMID: 21548473 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

4,830 results

Search Page

Filters